Correlation Between NewAmsterdam Pharma and Dermata Therapeutics

Specify exactly 2 symbols:
Can any of the company-specific risk be diversified away by investing in both NewAmsterdam Pharma and Dermata Therapeutics at the same time? Although using a correlation coefficient on its own may not help to predict future stock returns, this module helps to understand the diversifiable risk of combining NewAmsterdam Pharma and Dermata Therapeutics into the same portfolio, which is an essential part of the fundamental portfolio management process.
By analyzing existing cross correlation between NewAmsterdam Pharma and Dermata Therapeutics, you can compare the effects of market volatilities on NewAmsterdam Pharma and Dermata Therapeutics and check how they will diversify away market risk if combined in the same portfolio for a given time horizon. You can also utilize pair trading strategies of matching a long position in NewAmsterdam Pharma with a short position of Dermata Therapeutics. Check out your portfolio center. Please also check ongoing floating volatility patterns of NewAmsterdam Pharma and Dermata Therapeutics.

Diversification Opportunities for NewAmsterdam Pharma and Dermata Therapeutics

-0.64
  Correlation Coefficient

Excellent diversification

The 3 months correlation between NewAmsterdam and Dermata is -0.64. Overlapping area represents the amount of risk that can be diversified away by holding NewAmsterdam Pharma and Dermata Therapeutics in the same portfolio, assuming nothing else is changed. The correlation between historical prices or returns on Dermata Therapeutics and NewAmsterdam Pharma is a relative statistical measure of the degree to which these equity instruments tend to move together. The correlation coefficient measures the extent to which returns on NewAmsterdam Pharma are associated (or correlated) with Dermata Therapeutics. Values of the correlation coefficient range from -1 to +1, where. The correlation of zero (0) is possible when the price movement of Dermata Therapeutics has no effect on the direction of NewAmsterdam Pharma i.e., NewAmsterdam Pharma and Dermata Therapeutics go up and down completely randomly.

Pair Corralation between NewAmsterdam Pharma and Dermata Therapeutics

Given the investment horizon of 90 days NewAmsterdam Pharma is expected to generate 0.43 times more return on investment than Dermata Therapeutics. However, NewAmsterdam Pharma is 2.3 times less risky than Dermata Therapeutics. It trades about 0.11 of its potential returns per unit of risk. Dermata Therapeutics is currently generating about -0.03 per unit of risk. If you would invest  1,591  in NewAmsterdam Pharma on September 1, 2024 and sell it today you would earn a total of  394.00  from holding NewAmsterdam Pharma or generate 24.76% return on investment over 90 days.
Time Period3 Months [change]
DirectionMoves Against 
StrengthWeak
Accuracy100.0%
ValuesDaily Returns

NewAmsterdam Pharma  vs.  Dermata Therapeutics

 Performance 
       Timeline  
NewAmsterdam Pharma 

Risk-Adjusted Performance

9 of 100

 
Weak
 
Strong
OK
Compared to the overall equity markets, risk-adjusted returns on investments in NewAmsterdam Pharma are ranked lower than 9 (%) of all global equities and portfolios over the last 90 days. In spite of comparatively weak primary indicators, NewAmsterdam Pharma unveiled solid returns over the last few months and may actually be approaching a breakup point.
Dermata Therapeutics 

Risk-Adjusted Performance

0 of 100

 
Weak
 
Strong
Very Weak
Over the last 90 days Dermata Therapeutics has generated negative risk-adjusted returns adding no value to investors with long positions. Despite weak performance in the last few months, the Stock's primary indicators remain somewhat strong which may send shares a bit higher in December 2024. The current disturbance may also be a sign of long term up-swing for the company investors.

NewAmsterdam Pharma and Dermata Therapeutics Volatility Contrast

   Predicted Return Density   
       Returns  

Pair Trading with NewAmsterdam Pharma and Dermata Therapeutics

The main advantage of trading using opposite NewAmsterdam Pharma and Dermata Therapeutics positions is that it hedges away some unsystematic risk. Because of two separate transactions, even if NewAmsterdam Pharma position performs unexpectedly, Dermata Therapeutics can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Dermata Therapeutics will offset losses from the drop in Dermata Therapeutics' long position.
The idea behind NewAmsterdam Pharma and Dermata Therapeutics pairs trading is to make the combined position market-neutral, meaning the overall market's direction will not affect its win or loss (or potential downside or upside). This can be achieved by designing a pairs trade with two highly correlated stocks or equities that operate in a similar space or sector, making it possible to obtain profits through simple and relatively low-risk investment.
Check out your portfolio center.
Note that this page's information should be used as a complementary analysis to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Sync Your Broker module to sync your existing holdings, watchlists, positions or portfolios from thousands of online brokerage services, banks, investment account aggregators and robo-advisors..

Other Complementary Tools

Portfolio Manager
State of the art Portfolio Manager to monitor and improve performance of your invested capital
Piotroski F Score
Get Piotroski F Score based on the binary analysis strategy of nine different fundamentals
ETF Categories
List of ETF categories grouped based on various criteria, such as the investment strategy or type of investments
Financial Widgets
Easily integrated Macroaxis content with over 30 different plug-and-play financial widgets
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance